Introduction Executing compliant Impurity Control Strategies Under ICH Q3A and Q3B requires establishing scientific and toxicological parity with the Reference […]
Impurity Control Strategies Under ICH Q3A and Q3B for Generic Drug ANDA Submissions Read More »
Introduction Executing Generic Ophthalmic Suspension ANDA Development requires a coordinated technical strategy that integrates qualitative and quantitative sameness (Q1/Q2), structural
Introduction Designing a GMP-Compliant Extractables and Leachables (E&L) Study for container closure systems requires a systematic, risk-tiered analytical framework to
Introduction Extractables and Leachables (E&L) Requirements for Single-Use Bioprocessing in cell therapy programs define the analytical frameworks and risk assessment
Introduction Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers the sensitivity, mass accuracy, and structural resolution necessary for detecting, localizing, and quantifying
Introduction The fundamental Difference Between Biosimilar and Biologic Manufacturing from a quality perspective is rooted in the primary objective of
Introduction Reference Listed Drug (RLD) Sourcing and Reverse Engineering provide the essential scientific and regulatory foundation for Abbreviated New Drug
Reference Listed Drug (RLD) Sourcing and Reverse Engineering: The CDMO’s Role in ANDA Read More »
Introduction The use of Peptide-Oligonucleotide Conjugate (POCs) in CNS Drug Delivery represents an advanced bioconjugation strategy designed to transport therapeutic
Introduction Preparing a Full Characterization Data Package for a GLP-1 Receptor Agonist ANDA is a critical regulatory milestone for demonstrating
Introduction NDSRI Quantification at Ultra-Low Levels requires advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies capable of detecting mutagenic impurities at
